Genomma’s continued strong operating performance this quarter was again supported by our successful implementation of the key initiatives associated with Genomma’s new strategic priorities. The Company strong execution at our Mexico operations- and in many of the LatAm markets in which we have a presence- is further affirmation of our Company’s new growth path, supported by the four key strategic pillars of our strategy: Product Innovation and Portfolio Optimization, Best-in-Class Go-to-Market, Superior Supply Chain Capabilities and a Strengthened Corporate Culture. I’m confident that our continued discipline executing on these strategic pillars will continue driving Genomma Lab growth on a consistent basis. Further, the Sanitary License we were granted in early July for Genomma’s OTC manufacturing plant is a significant milestone for our Company, and one that we are delighted to have reached after a phase of considerable progress. This certification will enable us to continue with the regulatory process and obtain initial GMPs for solid and semi-solids production for the Mexican market.
Chief Executive Officer
July 24, 2019